Greenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Rhea-AI Summary

Greenwich LifeSciences (NASDAQ:GLSI) will feature in a sponsored RedChip television interview discussing its GLSI-100 breast cancer immunotherapy development program. The interview airs on Bloomberg TV November 14, 2026, at 7:00 p.m. ET and CNBC November 15 at 11:30 a.m. ET.

GLSI-100 demonstrated an approximately 80% reduction in breast cancer recurrence in a Phase IIb trial. Greenwich also reports an approximately 80% reduction in the ongoing Phase III FLAMINGO-01 trial's open-label, non-HLA-A02 cohort, based on preliminary observations requiring further validation. The company estimates broader eligibility could potentially double its annual target population from approximately 44,000 to 88,000 patients across the United States and Europe. Enrollment continues across approximately 160 clinical sites, with potential expansion to approximately 200. Greenwich is pursuing protocol modifications to expand eligibility and strengthen planned interim analyses.

6 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointGLSI-100's Phase IIb trial demonstrated an approximately 80% reduction in breast cancer recurrence.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Broader eligibility could potentially double Greenwich's annual target population from approximately 44,000 to 88,000 patients across the U.S. and Europe.
• Minor pointPhase III non-HLA-A02 cohort showed an approximately 80% recurrence reduction based on the company's preliminary observations.
• Minor point. Forward-looking: it has not happened yet and may not happen.Trial enrollment continues across approximately 160 sites, with potential expansion to approximately 200.
• Minor point. Forward-looking: it has not happened yet and may not happen.Protocol modifications are being pursued to expand eligibility and strengthen planned interim analyses.
• Minor pointCommercially manufactured GLSI-100 supplies are being used in the U.S. Phase III trial.

Negative

• Minor pointPhase III non-HLA-A02 recurrence findings remain preliminary and require further validation.

Key Figures

Recurrence reduction: approximately 80% Recurrence reduction: approximately 80% Annual target population: approximately 44,000 to 88,000 patients +2 more

Recurrence reduction

approximately 80%

Phase IIb clinical trial

Recurrence reduction

approximately 80%

Preliminary observations in the open-label non-HLA-A02 cohort

Annual target population

approximately 44,000 to 88,000 patients

Potential broader eligibility across the United States and Europe

Clinical sites

approximately 160 sites

Across the United States and Europe

Potential trial sites

approximately 200 sites

Potential expansion

Key Terms

her2-positive, gm-csf, open-label, hla type

4 terms

her2-positive medical

"GLSI-100, a novel immunotherapy designed to prevent the recurrence of HER2-positive breast cancer."

HER2-positive describes cancer cells that have too many copies of the HER2 gene or make too much of the HER2 protein, which acts like an overactive growth switch that drives tumor growth. For investors, HER2 status matters because it determines whether patients can receive specific, often expensive targeted therapies and diagnostic tests, so trial results, approvals, or competing drugs tied to HER2 can strongly affect drug sales and company value.

gm-csf medical

"GLSI-100 combines the GP2 peptide with GM-CSF"

GM‑CSF is a naturally occurring immune signaling protein that tells certain white blood cells to grow, move and fight infection — like a traffic cop directing immune cells to where they’re needed. Investors care because drugs that boost or block GM‑CSF can treat cancers, inflammatory conditions or infectious diseases, so clinical trial results, approvals, dosing and safety concerns can materially affect a biotech or pharmaceutical company’s clinical and commercial prospects.

open-label medical

"The open-label, non-HLA-A02 patient cohort"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

hla type medical

"strong immune responses and preliminary recurrence trends in patients regardless of HLA type."

HLA type is the genetic pattern of proteins on a person’s cells that help the immune system tell self from foreign tissue; doctors identify it by “typing” the genes that control these markers. Investors should care because HLA types affect how patients respond to transplants, vaccines, and certain drugs, so they can shape clinical trial results, regulatory approval, and the market size for therapies—like matching puzzle pieces, the right fit determines success or failure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ORLANDO, FL / ACCESS Newswire / November 13, 2026 / RedChip Companies will air an interview with Greenwich LifeSciences, Inc. (NASDAQ:GLSI) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, November 14, at 7:00 p.m. Eastern Time (ET), and on CNBC this Sunday, November 15, at 11:30 a.m. ET. Bloomberg TV is available in an estimated 73 million homes across the United States, and CNBC is available in approximately 90 million U.S. households.

Access the interview in its entirety at: https://www.redchip.com/assets/access/glsi_access

Snehal Patel, CEO of Greenwich LifeSciences, joins the RedChip Small Stocks, Big Money™ show to discuss the Company's progress in developing GLSI-100, a novel immunotherapy designed to prevent the recurrence of HER2-positive breast cancer. GLSI-100 combines the GP2 peptide with GM-CSF to stimulate the immune system to recognize and eliminate recurring cancer cells following surgery and standard antibody treatment. In a Phase IIb clinical trial, GLSI-100 demonstrated an approximately 80% reduction in breast cancer recurrence, supporting its potential to address a significant unmet medical need and reduce the risk of metastatic disease.

Patel highlights encouraging early findings from the Company's ongoing Phase III FLAMINGO-01 trial, including strong immune responses and preliminary recurrence trends in patients regardless of HLA type. The open-label, non-HLA-A02 patient cohort has shown an approximately 80% reduction in recurrence based on the Company's preliminary observations, consistent with results from the earlier Phase IIb study. These findings, while still early and requiring further validation, could support expanding GLSI-100's addressable patient population beyond the initially targeted HLA-A02 group. Greenwich estimates that broader eligibility could potentially double its annual target population from approximately 44,000 to 88,000 patients across the United States and Europe.

The interview also explores Greenwich's clinical development milestones, global trial expansion, and preparations for potential commercialization. With approximately 160 clinical sites across the United States and Europe, the Company continues to advance patient enrollment while pursuing protocol modifications designed to expand eligibility and strengthen its planned interim analyses. Patel also discusses progress in commercial-scale manufacturing, including FDA review of manufacturing data and the use of commercially manufactured GLSI-100 clinical supplies in the U.S. Phase III trial. With additional clinical data presentations anticipated, a potential expansion to approximately 200 trial sites, and interim analyses ahead, Greenwich is positioning GLSI-100 for its next stage of clinical development while exploring opportunities to expand the immunotherapy's potential applications.

GLSI is a client of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About Greenwich LifeSciences

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. Founded in 1992 as a small-cap research firm, RedChip gained early recognition for initiating coverage on emerging blue chip companies such as Apple, Starbucks, Daktronics, Winnebago, and Nike. Over the past 34 years, RedChip has evolved into a full-service investor relations and media firm, delivering concrete, measurable results for its clients, which have included U.S. Steel, Perfumania, Cidara Therapeutics, and Celsius Holdings, among others. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US and CNBC; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

Sign Up for RedChat

RedChat™ is an AI-powered investment research assistant designed to give investors instant access to critical insights from SEC filings, press releases, and corporate disclosures. Built to streamline small-cap and microcap stock research, RedChat analyzes thousands of public company documents and delivers clear, context-rich answers to investor questions in seconds. Instead of manually reviewing lengthy filings, investors can simply ask RedChat about financial results, partnerships, business strategy, or recent announcements and receive precise, source-based summaries. Investors can experience RedChat and start exploring stocks today at www.redchip.com/stocks or www.red.chat.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Disclaimer

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Certain statements regarding Greenwich LifeSciences Inc. ("Greenwich LifeSciences") and its business, operations, plans and prospects may constitute forward-looking statements and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Investors should review Greenwich LifeSciences' respective regulatory filings for additional information regarding the companies and the risks associated with an investment in their securities.

RedChip Companies, Inc. provides investor relations and media services to Greenwich LifeSciences and receives compensation for those services. Visit https://www.redchip.com/legal/disclosures for details. The information regarding Greenwich LifeSciences contained in this release has been derived from information provided by the respective companies or from publicly available sources. RedChip does not independently verify all such information and makes no representation or warranty as to its accuracy or completeness. Nothing contained herein should be construed as investment advice or a recommendation to buy or sell any security.

Contact:

Dave Gentry
RedChip Companies Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
info@redchip.com

--END--

SOURCE: RedChip Companies, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Greenwich LifeSciences report about GLSI-100 breast cancer recurrence results?

GLSI-100 demonstrated an approximately 80% reduction in breast cancer recurrence in a Phase IIb trial. Greenwich also reports an approximately 80% reduction in the ongoing Phase III trial's open-label, non-HLA-A02 cohort, based on preliminary observations that require further validation.

What manufacturing progress has Greenwich LifeSciences reported for GLSI-100?

Commercially manufactured GLSI-100 clinical supplies are being used in the U.S. Phase III trial. The interview also covers commercial-scale manufacturing progress, including FDA review of manufacturing data.